Expectations trend
FY2028 · fiscal year ending 2028-03-31 · fmp
IGC PHARMA INC (IGC)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$0.19-3.08%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IGC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital structure and financing arrangements | IGC Pharma is working to manage its capital and extend financing to support operations. | Intact | Failure to secure or extend financing agreements leading to liquidity shortfall | Financing extended (O-Bank, Apr 2026) IGC extended its Master Loan and Security Agreement with O-Bank in June 2026, securing continued liquidity support. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-03-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
IGC is a speculative, trial-dependent healthcare business rather than an established earnings compounder. Its thesis is in a watch state: trial progress is a positive sign, but recent financial performance remains weak and the evidence is mixed.
The valuation model indicates IGC is expensive versus peers, with a durable premium, but confidence in that assessment is low. The expectations gap is large, and the snapshot labels the pricing as unjustified, suggesting the premium is not well supported by current operating results.
Near term, revenue and gross profit have declined across the reported period, while operating losses and negative net income show that trial progress has not yet improved financial performance. CALMA, the Phase 2 trial for IGC-AD1 in Alzheimer’s agitation, has more than 80% dosing completion and interim data showing reduced agitation at two weeks, but results remain early; financing arrangements and equity issuance are also important to monitor.
Over the next one to three years, the thesis hinges on whether CALMA advances and produces evidence that supports further development, while management addresses losses and improves revenue and gross profit. Near-term sentiment also depends on broader conditions: a weakening jobs trend could weigh on cyclical names, while healthcare bellwethers’ results may either sustain or weaken the sector tailwind.
IGC has a potentially important clinical catalyst, but the multi-year view remains highly uncertain because operating performance is declining and the valuation premium has weak support in the evidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Net income has improved from -$5.6M in 2024-Q3 to -$1.8M in 2026-Q2, showing some progress toward profitability. |
| Broken |
| Net income worsens or operating losses deepen beyond -$2.9M |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 8 of last 8 quarters. Operating income worsened from -$1.76M in 2025-Q2 to -$2.78M in 2027-Q1, and net income declined from -$1.72M to -$2.94M. Despite management's commitment, operating losses and net losses have increased, indicating a declining financial trajectory. Delivery assessment Oct 12, 2026 |
Improve revenue and gross profit | The company aims to improve revenue and gross profit, despite recent declines. | Broken | Revenue and gross profit decline further below 2026-Q2 levels | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 8 of last 8 quarters. Revenue declined from $412K in 2025-Q2 to $265K in 2027-Q1, and gross profit fell from $198K to $48K over the same period. Despite management's focus on improving these metrics, financials show a declining trajectory, indicating limited progress. Delivery assessment Oct 12, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.08 → $-0.08 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.08 | $857,000 | 1 / 1 |
| 2026-07-25 | $-0.08 | $857,000 | 1 / 1 |
| 2026-07-26 | $-0.08 | $857,000 | 1 / 1 |
| 2026-07-27 | $-0.08 | $857,000 | 1 / 1 |
| 2026-07-28 | $-0.08 | $857,000 | 1 / 1 |
| 2026-07-29 | $-0.08 | $857,000 | 1 / 1 |
| 2026-07-30 | $-0.08 | $857,000 | 1 / 1 |
| 2026-07-31 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-01 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-02 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-03 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-04 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-05 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-06 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-07 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-08 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-09 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-10 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-12 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-13 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-14 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-15 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-16 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-17 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-18 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-19 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-20 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-21 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-22 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-23 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-24 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-25 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-26 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-27 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-28 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-29 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-30 | $-0.08 | $857,000 | 1 / 1 |
| 2026-08-31 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-01 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-02 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-03 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-04 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-05 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-06 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-07 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-08 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-09 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-10 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-11 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-12 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-13 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-14 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-15 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-16 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-17 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-18 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-19 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-20 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-21 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-22 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-23 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-24 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-25 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-26 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-27 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-28 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-29 | $-0.08 | $857,000 | 1 / 1 |
| 2026-09-30 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-01 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-02 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-03 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-04 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-05 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-06 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-07 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-08 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-09 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-10 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-11 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-12 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-13 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-14 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-15 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-16 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-17 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-18 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-19 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-20 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-21 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-22 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-23 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-24 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-25 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-26 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-27 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-28 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-29 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-30 | $-0.08 | $857,000 | 1 / 1 |
| 2026-10-31 | $-0.08 | $857,000 | 1 / 1 |
| 2026-11-01 | $-0.08 | $857,000 | 1 / 1 |
| 2026-11-02 | $-0.08 | $857,000 | 1 / 1 |
| 2026-11-03 | $-0.08 | $857,000 | 1 / 1 |
| 2026-11-04 | $-0.08 | $857,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.